>98%

Store at -20℃ for one year（Powder）；Store at 2-4℃ for two weeks；Store at -20℃ for six months after dissolution.

MK 801; MK801; C13737

Powder

DMSO：67 mg/mL (198.59 mM)

Ethanol：7 mg/mL (20.74 mM)

NMDA receptor

Neurophysiological studies in vitro, using a rat cortical-slice preparation, demonstrates a potent, selective, and noncompetitive antagonistic action of dizocilpine on depolarizing responses to N-Me-D-Asp but not to kainate or quisqualate. The potencies of phencyclidine, ketamine, SKF 10047, and the enantiomers of dizocilpine as N-Me-D-Asp antagonists correlate closely (r = 0.99) with their potencies as inhibitors of dizocilpine binding. This suggests that the dizocilpine binding sites are associated with N-Me-D-Asp receptors and provides an explanation for the mechanism of action of dizocilpine as an anticonvulsant.

All the control rats have severe permanent neurological deficits after ischemic spinal cord injury (ISCI), whereas the dizocilpine–treated rats have statistically (P

[1] Wong EH et al., Proc Natl Acad Sci U S A, 1986, 83(18), 7104-7108.
[2] Wise-Faberowski L et al., J Neurosurg Anesthesiol, 2006, 18(4), 240-246.
[3] Kocaeli H et al., Surg Neurol, 2005, 64 Suppl 2, S22-S26.